FDA approves Garzulys (insulin aspart-fsan) as a rapid-acting biosimilar to NovoLog for adult and pediatric patients with diabetes mellitus.
Elevated herpesvirus-directed responses and antiflagellin antibodies seen up to 10 years prediagnosis in Crohn disease ...
Despite noting the high unmet need in Duchenne muscular dystrophy, the FDA panel concluded that trial data lacked substantial evidence of the therapy's effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results